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Summary  
Idiosyncratic hepatotoxicity is an adverse reaction that can be evoked by certain drugs. The characteristic of this rare event is its occurrence at therapeutic doses that are usually well tolerated by the patients, and most importantly, this toxicity frequently becomes manifested in a specific population of subjects. These motifs point towards underlying or acquired genetically and/or environmental risk factors rendering some patients more susceptible to idiosyncratic adverse reactions. Although the mechanisms of drug-induced liver injuries are not completely understood, mitochondrial dysfunction and/or formation of toxic metabolites have been recognized as major contributors in many cases of idiosyncratic hepatotoxicity. Moreover, predisposing mitochondrial dysfunction has been suspected to be one of the factors enhancing the risk for idiosyncratic toxicity. Therefore, severe inhibition of cellular metabolic functions, maintained by the mitochondria, an organelle crucial for proper energy homeostasis and delivery for the cell, may induce oxidative stress that in turn can result in cell death and ultimately to liver dysfunction and death. The lack of reliable methods to identify substances with the risk for idiosyncratic mitochondrial toxicity represents a major issue for the pharmaceutical industry, since unpredicted idiosyncratic toxicity can consequence in withdrawal of the drug from the market or in warnings by health authorities. It is thus an important need to characterize drugs that are related to idiosyncratic toxicity for a better understanding of implicated mechanisms and also to develop suitable in vitro and in vivo systems that can be applied to test drugs for their idiosyncratic potential.  This thesis includes three papers that have been published or submitted for publication and a short report as pilot project. The first two projects and the short report present the development of an in vitro and in vivo system with underlying mitochondrial defects that could serve as tool to uncover drugs with an increased risk for idiosyncratic toxicity, whereas the third project addresses the molecular mechanisms of hepatotoxicity in vitro of the antimitotic agents of azoles.  Our first paper describes a newly developed in vitro model in HepG2 cells induced by the chemical hydroxy-cobalamin [c-lactam] (HCCL), a vitamin B12 analog. The model exhibits subtle changes in the respiratory chain function and slight increase of oxidative stress leading to mitochondrial swelling. HCCL is known to competitively inhibit proper processing of substrates of the propionate pathway and causes similar defects as seen for the inherited metabolic disorder methylmalonic aciduria. We showed that subtoxic concentrations of HCCL could impair mitochondrial function and thus used this model that should reflect preexisting mitochondrial diseases of patients rendering them more susceptible to mitochondrial toxicants. In this context, we demonstrated that known mitochondrial toxicants applied on our HCCL model exert increased toxicity, which supports the hypothesis that risk factors such as underlying mitochondrial defects 
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predispose for idiosyncratic toxicity of compounds that have a known adverse mechanisms on mitochondrial function such as dronedarone, benzbromarone, and ketoconazole.  Our second paper aimed to expand the results obtained from the HCCL in vitro study into a mouse model. We showed that daily i.p. treatment of HCCL over three weeks induced an elevation of methylmalonic acid, a marker of methylmalonic aciduria. Moreover, slight decrease of complex I of the electron transport chain in liver homogenates were observed. Histopathological analysis revealed enhanced glycogen content and fat accumulation in the liver explaining the observed elevation of liver weight. Besides that, we did not find any increased oxidative stress or other dysfunctions of the mitochondria due to HCCL exposure. Because of the metabolic changes found in this study were minor, we did not further pursue the exploration of this model in order to test idiosyncratic drugs on it.  The third paper focused on the discovery of the molecular mechanisms of hepatotoxicity of antifungal azoles. Cytotoxicity experiments in HepG2 cells uncovered dose-dependent toxicity of ketoconazole and posaconazole, whereas fluconazole and voriconazole did not affect the cells. Toxicity studies in HepaRG cells did not point at any implication of metabolites for all four tested azoles. Our functional examination on mitochondrial function of ketoconazole and posaconazole depicted a strong inhibitory potential on the respiratory chain function, accompanied by oxidative stress and apoptosis, suggesting mitochondrial dysfunction responsible for azole-induced hepatotoxicity. The exposure of these two mitochondrial toxins on our previously created HCCL in vitro model evidenced an increased toxicity already at therapeutic concentrations, strongly supporting the assumption that preexisting mitochondrial defects can lower the threshold level of a drug’s toxicity and thereby a manifestation of idiosyncratic hepatotoxicity. Lastly, the short report readopts the subject of the establishment of in vitro models with mitochondrial dysfunction, implementing it as system for testing idiosyncratic toxicity. With siRNA we depleted two different essential mitochondrial enzymes, SIRT3 or SOD2, in HepG2 cells. We hypothesized to find an increase in cytotoxicity and enhanced oxidative stress after exposure to known mitochondrial toxicants if cells either present depletion in the deacetylation of mitochondrial proteins or a silencing of one of the major antioxidant defense systems. However, our results did not reflect this assumption and did not reveal any enhanced toxicity of HepG2 cells lacking specific mitochondrial functions compared to normal HepG2 cells. Furthermore, induction of a second stress factor such as the removal of glutathione in SOD2 siRNA cells did not increase the susceptibility of these cells to mitochondrial toxicants. Nevertheless, with this study we presented interesting basic approaches how to establish models to test idiosyncratic toxicity in vitro.  
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Background 
1. Drug-induced liver injury (DILI) 
The liver, as principle site of drug metabolism, has been considered as the most important organ in drug toxicity. The liver is responsible for drug metabolism, and therefore for the elimination of drugs from the body. At the same time, these features render the liver as preferential target for drug toxicities. Drug-associated hepatotoxicity is involved in more than 50% of all cases of acute liver failure in the US, with idiosyncratic drug-induced liver injury as the most common cause of toxicity [1, 2]. Hepatotoxicity has been the major reason of post-marketing drug withdrawal in the last past decades [3]. Moreover, many drug warnings, failures, or withdrawals have been ascribed to mitochondrial toxicity [4-6]. Since drug-induced hepatotoxicity occurs very rarely it often remains undetected during drug development, as only a few thousand subjects participate in the clinical phases.  Although DILI has low estimated incidence rates of 1/100’000 to 1/10’000 exposed patients [3], in reality, the incidence cases are most-likely underestimated, due to the lack of reporting or surveillance systems, standardized nomenclature or causality assessment methods, but also because of the difficulty to evaluate the number of patients additionally taking over the counter or herbal medicines, beside the prescribed medications [7]. Therapeutic drug classes including antibiotics, antinflammatory, antipsycotics, and antimycotics, as well as herbal products and dietary supplements are implicated with DILI [8-10]. 
1.1. Definition DILI can show different clinical patterns, starting from asymptomatic or transient elevation of liver biomarkers, to jaundice or severe acute liver failure, and rarely ending in chronic liver diseases. Many different terminologies of DILI made accurate clinical diagnosis difficult; therefore Aithal et al. communicated a standardized synopsis in terms of threshold criteria for identification, pattern of injury, causality assessment, and severity to facilitate the diagnosis of DILI [11]. Originally, the clinically relevant threshold level for DILI was defined as the elevation of serum concentration of either alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin exceeding twice the upper limit of normal (ULN). These definitions were adjusted due to unspecific elevations of transaminases that would be counted as DILI. 
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 Thus the threshold level was set at AST or ALT > 5 X ULN without symptoms, or rise in ALP > 2 X ULN, or rise in bilirubin > 2 X ULN with any increase in AST and ALT concentration [10, 11].  DILI can be classified as either hepatocellular, cholestatic or mixed types, based on the degree of elevation of transaminases and ALP and the ratio of increased baseline ALT to baseline ALP (R= (ALT/ULN)/(ALP/ULN)) (see Table 1). The severity of DILI does not correlate with the level of liver enzymes elevation, however, the pattern gives information about the immediate and long-term consequences [10, 11].  
Table 1: Liver injury patterns and examples of hepatotoxic drugs adapted from Weiler et al. [12] 
Type of liver injury Hepatocellular Mixed Cholestatic  Injury predominantly to hepatocytes Hepatocellular and cholestatic injury Injury to bile ducts or affecting bile flow R-Value ≥5 >2 and <5 ≤2 [R=(ALT/ULN)/(ALP/ULN)]    
Examples of drugs classes    
Antiinfectives Isoniazid, ketoconazole, tetracylines Erythromycin, amoxicillin/clavulanic acid, cotrimoxazole 
Amoxicillin/clavulanic acid, erythromycin 
Pain reliefers Acetylsalicylic acid, acetaminophen   
Cardiovascular and metabolic 
drugs Lorsartan, statins, allopurinol Enalapril, verapamil Clopidogrel 
Neurologic/Psychiatric drugs Valproic acid Carbamazepine, phenytoin  Chlorpromazine, tricyclic antidepressants ALT, alanine aminotransferase; ALP, alkaline phosphatase; R, ratio; ULN, upper limit normal 
1.2. Discriminative terms: Intrinsic vs. idiosyncratic reactions The basic mechanism of DILI can be distinguished in two different types; a) intrinsic “type A reaction” or b) idiosyncratic “type B reaction” (Table 2). Drugs that cause liver injury in a dose-dependent manner are typically referred to as intrinsic. They are predictable in humans or in animal models [6]. The most prominent drug with high potential of intrinsic DILI is the widely used pain reliever acetaminophen (APAP) [13]. Although APAP is very safe at therapeutic doses, APAP induces massive hepatocellular necrosis, when overdosed (> 4 g/d). The mechanism behind this phenomenon is the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is formed during drug metabolism depleting the antioxidant glutathione content in cells 
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resulting in mitochondrial dysfunction culminating in cell death and subsequent acute liver failure [13, 14]. Unlike intrinsic toxicity, the idiosyncratic phenotype occurs very rarely, is unexpected, not strictly dose-dependent, affects only a small proportion of patients (< 1%), and cannot either be predicted by its pharmacology or from conventional clinical toxicology tests [8]. This implies that idiosyncratic toxic adverse reaction usually appear at therapeutic doses and in a specific population of patients [10]. In most cases, clinical features are visible within 5-90 days after the causative medication was started [7]. It is difficult to explain the underlying mechanisms why certain patients seem to be more susceptible to idiosyncratic DILI than others. As the mechanisms of intrinsic DILI can be understood and explained with animal models, to date there are no established preclinical in vivo or in vitro models successfully predicting idiosyncratic toxicity for new drug entities. Therefore, idiosyncratic DILI represents a major issue not only for the patients’ safety but also in perspective of the pharmaceutical industry [3].  
Table 2: Characteristics of type A and type B adverse reactions, adapted from Pessayre D [15]. 
Characteristics Type A (intrinsic) Type B (idiosyncratic) 
Dose dependency Yes No simple relationship 
Predictable from known 
pharmacology Yes Usually no 
Host factors Genetic factors are less important Dependent on susceptibility factors (e.g. genetic factors, drug interactions) 
Incidence High Low 
Severity Variable, dose dependent Variable, more severe 
Latency period Short (days) Few days-months 
Clinical burden High morbidity, possible mortality High morbidity and mortality 
Experimental reproducibility Yes, animal models Only few animal and cell models 
Examples of drugs Acetaminophen Phenytoin, cotrimoxazole 
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1.3. Risk factors implicating idiosyncratic toxicity Although idiosyncratic DILI are traditionally defined as not clearly dose-dependent, recent studies showed that just as daily doses over 50 mg, greater lipophilicity of drugs, and/or extensive hepatic metabolism usually predispose for DILI [16, 17]. Moreover, increased risk associated with idiosyncratic DILI was observed in females with an incidence of 65% [18]. Also underlying liver diseases could account for a higher susceptibility for DILI, but conflicting reports and studies render this determinant indistinct [7]. However, more likely the combination of drug-drug interactions, reactive metabolites, environmental, and genetic factors are believed to account for idiosyncratic DILI (see Figure 1) [19].  The genetic susceptibility may be one of the most important factors leading to DILI. One prominent example for idiosyncratic DILI is the allele HLA-B*5701, a subclass of the human leucocyte antigen (HLA) system. Daly et al. [20] have examined in a European cohort study that the possession of a HLA-B* allele attributed to a 80-fold increased risk for flucloxacillin-induced liver toxicity. Many genetic polymorphisms of enzymes have been extensively studied the last few years and have helped to characterize pathogenic mechanisms of DILI in individual patients. Nevertheless, genome-wide association studies of pooled cases could not clearly relate genetic factors with idiosyncratic DILI [21]. Further, underlying defective health conditions, such as preexisting inborn mitochondrial cytopathies affecting metabolic function are supposed additive triggering factors, leading to drug-induced idiosyncratic hepatotoxicity that possibly is not manifested in healthy subjects [15].  
 
Figure 1: Potential risk factors implicated in the 
pathogenesis of “Idiosyncratic” DILI 
as illustrated by Fontana et al. [8]. A) 
Drug-drug or drug-disease interactions 
could alter the concentration of a drug or 
reactive metabolite at a cellular level in-
volved in the initiation, maintenance or 
resolution of liver injury. B) Clinical host 
risk factors such as age, body weight, 
and BMI can enhance the development 
of DILI. C) Diverse micro and 
macroenvironment of individuals receiv-
ing medications can potentiate the 
hepatotoxic risk of a drug. 
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1.4. Mechanistic classification of DILI Commonly, idiosyncratic adverse reactions are either classified as immune- or metabolic-mediated DILI. The first is often referred as an allergic or ‘hypersensitivity’ reaction. General features of the immune-mediated adverse reactions are its early onset (1-6 weeks) and its fast reinjury with reexposure. Often hypersensitive reactions are implicated with anticonvulsive drugs (phenytoin, carbamazepine), where typical symptoms and signs of the adaptive immune system such as fever, rash, and formation of autoantibodies appear [10]. In contrast, metabolic-mediated DILI, assumed to be evoked by reactive metabolites, typically have a later onset (1-52 weeks), variable response rate, no manifestation of hypersensitivity, and usually no recurrence after rechallenge [7]. This traditional classification is probably too simplistic due to the multistep process of idiosyncratic DILI involving not only immune-and metabolic-mediated, but also genetic and environmental factors. Hence, Russmann et al. [22] postulated a three-step working model that restricts its principle mechanism to three main ways of initial injury, emphasizing the importance of unspecific downstream events following drug-specific initial upstream hepatic injury considering genetic and environmental risk factors. According to his model, illustrated in Figure 2, drugs or their metabolites initially cause direct cell stress (intrinsic pathway), trigger immune reactions (extrinsic pathway), and/or directly impair mitochondrial function. Second, after this primary hit, mitochondrial permeability transition may occur, which can initiate in a third step, apoptosis or necrosis. All these levels can be influenced by environmental or genetic factors, which in turn, in their complex interaction, function as triggering risk factors inducing idiosyncratic DILI. This means that normally one single risk factor may be not sufficient to initiate DILI. Underlying mild liver damage is probably not strong enough to disturb the fragile balance between impairing and protective factors on a cellular level, whereas another co-factor can amplify the effect and thus lead to severe idiosyncratic hepatotoxicity. This threshold theory of cumulative damages to mitochondrial targets could explain the late onset of idiosyncratic DILI [1, 23]. Therefore, the delayed onset of liver injury is most likely due to the prolonged injury to the mitochondria. Oxidative stress or impairment of mitochondrial function has first to pass a given threshold before apoptosis and necrosis, and resulting liver damages get manifested [1]. 
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.  
Figure 2: Integration of genetic and environmental risk factors derived from the three-step 
mechanistic working model of DILI with a pie model of disease causation as explained and 
illustrated by Russmann et al. [24]. Some risk factors may exert their effects on different 
consecutive hepatotoxic mechanisms and are therefore shown more than once. Multiple causes 
and their complex interactive contribution to DILI vary for different drugs and between individual 
patients, and remain poorly understood. In addition, it is also likely that there are other currently 
unknown risk factors. This model also implies that environmental factors play an important and 
sometimes even necessary triggering role. Genetic risk factors alone may therefore not be sufficient 
to predict a high absolute risk of DILI in individual patients. CAR, constitutive androstane receptor; 
DISC, death-inducing signaling complex; EtOH, ethanol; Nrf2, nuclear factor (erythroid-derived 2)-
related 2. 
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2. Principles of mitochondrial function and drug-induced 
mitochondrial toxicity  
In recent years, the mitochondrion has been more widely recognized as important drug biosensor, being a key off-target of drugs inducing idiosyncratic DILI. A lot of compounds causing metabolic failure are highly associated with impaired mitochondrial function [4, 25, 26]. Thus, mitochondrial toxicity has become a major issue in drug development, being the reason of many drug candidate failures, black box warnings or withdrawal from the market (see Table 3) [27].  
Table 3: Drugs associated with idiosyncratic hepatotoxicity by inhibition of mitochondrial function. 
Drug Indication Market status troglitazone antidiabetic withdrawn carbamezepine anticonvulsant black box warning benzbromarone uricosuric withdrawn diclofenac nonsteroidal inflammatory black box warning ketocoanzole antifungal black box warning/restriction ibufenac nonsteroidal inflammatory withdrawn valproic acid antieptileptic black box warining ticlopidine antiplatelet black box warning  Given that, as explained in the 3-step working model by Russmann et al. [22], the mitochondria play a pivotal role in the regulation of cellular function such as the supply of 90% of the overall cellular energy through processes of oxidative phosphorylation (OXPHOS), it is evident that a damage at a specific or different mitochondrial targets lead to multitissue toxicity. Particularly, mitochondria-rich organs such as the heart, brain, and/or liver that are highly working under aerobic conditions and relying on the energy-producing metabolism of the mitochondria render to be susceptible to mitochondrial toxicants [28]. Mitochondrial dysfunction thus can be induced by xenobiotics (or drugs) via a direct interaction of mitochondrial function or by an interference with mitochondrial transcription/translation and/or by increased superoxide anion production leading to oxidative stress [4, 29]. In the following paragraphs, basic principles of mitochondrial physiology and different mechanisms leading to an impairment of mitochondrial function will be described in detail.  
2.1. Morphology Mitochondria are constituted of two membrane systems, the outer and the inner mitochondrial membranes, both formed of phospholipid bilayers that are occasionally linked to each other like gap junction to form contact sites. The mitochondria are differentiated into distinct composi-
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tional and functional regions, where diverse transporting and enzymatic proteins are integrated. The space between these two membranes is called the intermembrane space, in which essential proteins (e.g. cytochrome C, creatine kinase) are located, playing a major role in cell homeostasis and mitochondrial energetics. The outer membrane, separating the mitochondrial from the cytosol is permeable for ions or molecules up to 6 kDa. This smooth membrane is rich in cholesterol and contains enzymes such as palmitoyl-CoA synthase, CPT1, and the mitochondrial permeability transition pore (MPTP) [30]. In contrast, the inner mitochondrial membrane is largely impermeable and cholesterol-free, separating the mitochondrial matrix from the cytosolic environment. This partition acts as chemical barrier maintaining the electron gradient across the membrane that enables ATP generation. Moreover, in the inner mitochondrial membrane, multiple invaginations (cristae) increase the surface area, which are formed into the matrix compartment that houses assembled respiratory complexes, and proteins for ATP synthesis and transport. These important constituents are the major targets of mitochondrial toxins [31]. Among the components of the matrix are several soluble enzymes essential for the citric acid cycle, β-oxidation, or urea synthesis [15, 32].  
2.2. Dynamics Mitochondria are organized as large branched structures, building a network that is always in constant movement to regulate fission or fusion, and therefore reorganizing the mitochondrial morphology either to highly fragmented or networked (see Figure 3) [33]. The mitochondrial form and function are thus closely linked to each other and are integrated into cellular signaling processes in a highly regulated way. Mitochondrial fusion is mediated by the two families of dynamin-like proteins mitofusin-1 (mfn1) and mitofusin-2 (mfn2) located in the OMM, and optic atrophy-1 (opa-1) located in the IMM. These proteins are responsible for the lengthening and the tethering of proximate mitochondria to build a network [34]. On the other hand, fission is involved in the division of mitochondria, mediated by the dynamin-related proteins drp-1 and fis-1. The splitting occurs in a manner that drp-1, by forming helical structures, is coiling around the mitochondria. Under healthy conditions, enhanced fusion creates mitochondrial tubular networks, whereas oxidative stress or other defects prevail mitochondrial fission, evoking a break up of the filamentous networks into fragmented mitochondria. Mitochondrial dysfunction is therefore tightly associated to the status of dynamics, at which mitochondrial fusion can buffer stress on the mitochondria [35].  
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Figure 3: Mitochondrial structure and network adapted from Rafelski et al. [36]. Examples of 
mitochondrial networks at the micron and nanometer scales. (a) Separate mitochondria in HepG2 
cells visualized by electron microscopy. (b) Diagram of the organization of the mitochondrial 
membranes (ultrastructure) at the nanoscale for (i) a tubule and (ii) a tubule branch. Abbreviations 
in (i) include the outer and inner mitochondrial membrane (OMM and IMM, respectively) and the 
intermembrane space (IMS). Mitochondrial networks can vary from separated structures to 
interconnected networks. (c) Indian Muntjac deer skin fibroblast (left) and BPAE (bovine pulmonary 
artery endothelial) cell (right), both expressing a pEYFP-mitochondrial plasmid vector to label 
mitochondria (yellow-orange). The thin yellow line is an approximate outline of the cell. White 
arrows point to small boxes indicating either a tubule (left) or tubule branch (right) that are 
illustrated in (b). 
2.3. Genome Mitochondria, only maternal inherited, are the unique organelles outside the nucleus, possessing their own genome with the singularity of self-replication independently of the nuclear genome [37]. The mitochondrial mtDNA consists of smaller double-stranded circular chromosomes (16 569 bp) encoding only a fraction of 13 essential proteins of which all are components of the electron transport chain (ETC) [38]. Other proteins, required for proper mitochondrial function are encoded by the nuclear genome and then translocated to the mitochondria [39]. The 24 other genes present on the mtDNA (2 rRNAs and 22 tRNAs) are all expressed to further synthesize the 13 essential proteins of the OXPHOS [40].  The mtDNA has a single DNA polymerase with base excision repair activity that ensures a precise replication of the mtDNA. However, the mutation rate of mtDNA is 5 to 20-fold higher than in nuclear DNA [38]. This discrepancy can be explained by the lack of protective proteins and less repairing pathways in the mtDNA, and moreover due to its proximity to the ETC, where 
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the majority of reactive oxygen species (ROS) is produced [41, 42]. Additionally, in contrast to the nuclear genome, the mtDNA is mostly irreparable or slowly repairable in terms of damage or stress. The only functional buffering system against stressors is the high copy number of mtDNA and renders thereby the mtDNA as fundamental biomarker for oxidative stress [41] . 
2.4. Principles of mitochondrial bioenergetics Mitochondria play a crucial role in oxidative metabolism and energy production, as they convert the energy (NADH and FADH2) produced by the oxidation of pyruvate-and free fatty acids, but also from the TCA cycle into ATP through OXPHOS [15, 43, 44]. Following sections discuss the three main energy-producing pathways of the mitochondria as illustrated in Figure 4. 
 
Figure 4: Bioenergetic functions of mitochondria adapted from Galluzzi et al,[45]. Critical bioenergetic 
circuitries mediated by the mitochondria, including the tricarboxylic acid (TCA) cycle, OXPHOS, and 
cycle, β oxidation. Despite glycolysis takes place in the cytosol, its intermediates are crucial for 
processes in mitochondrial bioenergetics. Note that several intermediate reactions and all 
transporters have been purposely omitted. α-KGDH indicates α-ketoglutarate dehydrogenase; 
ACDH, acyl-CoA dehydrogenase; ACO, aconitase; ALD, aldolase; ASL, argininosuccinate lyase; 
CoA, coenzyme A; Cyt c, cytochrome c; ECH, enoyl-CoA hydratase; ENO, enolase; G3PDH, 
glyceraldehyde-3-phosphate dehydrogenase; HCDH, 3-hydroxyacyl-CoA dehydrogenase; HK, 
hexokinase; IDH, isocitrate dehydrogenase; IMS, mitochondrial intermembrane space; MDH, 
malate dehydrogenase; PDH, pyruvate dehydrogenase; PFK1, phosphofructokinase-1; PGI, 
phosphoglucose isomerase; PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; PK, 
pyruvate kinase; SDH, succinate dehydrogenase; Q10, Q10 coenzyme. 
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2.4.1. β-Oxidation The degradation of fatty acids mainly occurs in the mitochondria and accounts for more than 
90% of the overall cellular β-oxidation; the residual 10% are credited to the peroxisomal pathway. β-oxidation occurs in the mitochondrial matrix in four steps, at which four distinct enzymes classes with broad specificity towards CoA-esters catalyze this reaction. In the first step an acyl CoA-ester is dehydrogenated to form a trans-2-enoyl-CoA, followed by a hydration of the double bond producing L-3-hydroxy-acyl-CoA. The third step leads to a dehydrogenation to 3-keto-acyl-CoA. At last, a thiolytic binding of 3-keto-acyl-CoA yields a two-carbon chain-shortened acyl-CoA and one acetyl-CoA (see Figure 4). Therefore, each cycle has a net production of acyl-CoA plus acetyl-CoA. Acyl-CoA undergoes another loop of β-oxidation while acetyl-CoA can directly enter the TCA cycle. In addition to the CoAs produced in each cycle, two reducing equivalents, NADH and FADH2, are formed and further processed by the ETC where NADH is oxidized by Complex I and FADH2 provides electrons to reduce coenzyme Q in Complex III. Thus, these two electron carriers display a direct junction of the β-oxidation and respiratory chain [46].  
An important mechanism of β-oxidation is the specific carnitine shuttle system that transports long-chain (C14-C18) fatty acids across the mitochondrial inner membrane into the mitochondrial matrix, where they are converted to the respective acyl-CoA an can be beta-oxidized. In contrast, short-chain (C4-C6) and medium-chain (C6-C14) fatty acids are able to freely cross the mitochondrial membranes [47].  
2.4.2. Odd-chain fatty acid β-oxidation When fatty acids with odd numbered carbons undergo β-oxidation, or during the oxidation of branched chain amino acids including isoleucine, valine, and methonine the result is acetyl-CoA and propionyl-CoA instead of the usually formed acetyl-CoA from the oxidation of even numbered fatty acids. Propionyl-CoA in contrast to acetyl-CoA, first has to be catabolized into succinyl-CoA in order to enter the TCA cycle. This conversion occurs via carboxylation of propionyl-CoA into D-methylmalonyl-CoA. Then, D-methylmalonyl-CoA is transformed to L-methylmalonyl-CoA through methylmalonyl-CoA epimerase. At the last step, methyl-malonyl-CoA mutase, a vitamin B12-dependent enzyme, catalyzes the rearrangement of L-methylmalonyl-CoA to succinyl-CoA, which is finally taken up by the TCA cycle and is converted to oxaloacetate (see Figure 5). Compared to even numbered fatty acids, odd numbered fatty acids occur in an irregular way. Nevertheless, the utilization of the propionate metabolism by several amino acids and cholesterol remain essential for proper metabolic functions [48, 49]. 
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Figure 5: Scheme of propionate pathway. 
2.4.3. Tricarboxylic (TCA) cycle The TCA cycle, better known as Krebs’ cycle, represents the gateway to aerobic metabolism. In a series of eight subsequent oxidation and reduction reactions (see Figure 4), two carbon molecules are oxidized to acetyl groups or dicarboxylic acids. This cycle is not only important providing precursors such as NADH and FADH2 for the transformation into ATP by the utilization of acetyl-CoAs delivered from β-oxidation or glycolysis; it also serves as basic element of different molecules such as amino acids, cholesterol, porphyrin, or nucleotide bases [50].  
2.4.4. Oxidative phosphorylation Through the process of OXPHOS, mitochondria produce cellular energy via ATP. The OXPHOS consists of two distinct, functionally independent processes by which 1) reduced substrates are oxidized by the ETC and 2) ADP is converted to ATP by inorganic phosphates via phosphorylation. As the OXPHOS metabolism of one molecule of glucose yields up to 36 molecules of ATP, it is much more efficient than glycolysis yielding only two ATP. The pathway of OXPHOS is constituted of five complexes (see Figure 6):  
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Figure 6: Mitochondrial energy production adapted from Bayir and Kagan [51].The mitochondrial ETC is 
composed of five multimeric complexes. Electron transport between complexes I to IV is coupled to 
extrusion of protons from complexes I, III and IV into the intermembrane space, creating an 
electrochemical gradient (Δψ) across the inner mitochondrial membrane. Protons then flow through 
complex V (ATP synthase), which utilizes the energy to synthesize ATP from ADP. C, cytochrome 
c; Q, ubiquinone. 
Complex I to IV compose the ETC, whereas complex V represents the ATP synthase. The complexes of the OXPHOS are embedded in the inner mitochondrial membrane and consist of various individual protein subunits, encoded either by the nucleus or the mitochondrial genome. The two reducing equivalents NADH and FADH2 derived from the TCA cycle are used by the OXPHOS to generate ATP [52]. Complex I, also known as NADH:ubiquinone oxidoreductase carries electrons from NADH to ubiquinone. Afterwards, Complex II (succinate:ubiquinone oxidoreductase) that is part of the TCA cycle further transfers the electrons from succinate to ubiquinone via FAD. At the stage of Complex III (ubiquinol:cytochrome c oxidoreductase), electrons from ubiquinol are transmitted to cytochrome c. At the ultimate step of the ETC, namely in Complex IV (cytochrome c oxidase), molecular oxygen (O2) is reduced to H2O by four electrons. This process of subsequent oxidation of reduced NADH in the ETC is coupled with oxidative phosphorylation by an electrochemical gradient (chemiosmotic potential) reaching a potential up to - 200 mV (Δψ) and a pH gradient across the mitochondria inner membrane. This efflux of protons to the intermembrane space enables a driving force of the FOF1 ATP synthase to generate ATP through ADP and inorganic phosphates, which is referred as Complex V [53].  
2.5. Production of reactive oxygen species and detoxifying systems The ETC is the major site of ROS formation, since 90% of cellular ROS is estimated to arise from mitochondrial ETC [54]. ROS, simply describing reactive molecules that are derived from O2 can appear as free radicals (O2-), hydroxyl radicals (OH-), and/or as non-radical hydrogen peroxide 
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(H2O2). The production of ROS is an elementary process of aerobic life, thereby mediating cellular function not only by promoting redox-sensitive signal transduction cascades or stimulating gene expression of antioxidant enzymes, but also inducing apoptosis or necrosis. ROS are generated as byproducts of the ETC; although under healthy conditions most of the electrons are transferred along the ETC in a regular manner, there is a constant amount (1-2%) of electrons intercepted by molecular oxygen and reduced to superoxide anion. Complex I and Complex III of the mitochondrial ETC have been identified as the major site of ROS production [55, 56].  Cellular antioxidant defense enzymes are able to metabolize accumulated ROS (see Figure 7). The most prominent enzymatic scavenger systems are superoxide dismutase (SOD), catalase, or hydroxyl peroxidases such as glutathione peroxidase [57]. Acting as a radical interceptor, SOD is catalyzing the dismutation of two superoxide anion radicals in the reaction with hydrogen in order to form H2O2 (2O2- + 2H+ -> H2O2 + O2). This enzyme appears in different isoforms. SOD1 or CuZN-SOD is located in the cytoplasm and mitochondrial intermembrane space, whereas the manganese SOD2, or better known as MnSOD is exclusively located in the mitochondrial matrix. SOD3, a Cu/Zn SOD resides in extracellular compartments [58]. It has been shown that mice lacking SOD2 survive only several days after birth, implicating that SOD2 represents as critical mediator for cell survival controlling a dense level of mitochondrial superoxide anion [59].  Once H2O2 is formed, it can easily diffuse through mitochondrial membranes, in contrast to the superoxide radicals that have limited permeability and a short half-life. Therefore other protective mechanisms have to remove H2O2, which can form highly reactive radicals through the spontaneous reaction with ferrous ions (Fe2+) affecting proteins, DNA, or lipids. Catalase, mainly expressed in peroxisomes is able to detoxify H2O2 to H2O and O2. Alternatively, glutathione peroxidase uses reduced GSH that serves as electron donator leading to an oxidation to cysteine disulfide bonds (GSSG) to reduce H2O2 to water. Afterwards, GSSG is reduced back to GSH in presence of nicotamide adenine dinucleotide phosphate (NADPH). GSH-based systems, highly expressed in the liver, constitute the most substantial redox buffer in the cytosol, where the GSH/GSSG predominates compared to other pathways involved in susbstrate reduction. After the exclusive biosynthesis in the cytosol, GSH is transported into intracellular organelles including the nucleus, endoplasmatic reticulum, and mitochondria. GSH in the mitochondria is mainly found in its reduced form, where it only represents a small fraction of 10-15% of the total cellular GSH pool. Considering the volume of the mitochondrial matrix, mitochondrial GSH concentrations can reach similar milimolar ranges (∼10 mM) as in the cytosol [43, 60-63]. .   
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Figure 7: Major ROS detoxifying systems adapted from Bashan [64]. The 
major enzymes of ROS detoxification are shown in blue. GPx, 
glutathione peroxidase; GR, glutathione reductase; GSH, reduced 
glutathione; GSSG, oxidized glutathione; SOD, superoxide dismutase. 
2.6. Mitochondrial signaling In recent years, the signaling pathway mediated by the sirtuin (SIRT) family has gained much attention in regulating cellular energy metabolism. SIRT proteins are highly conserved and possess NAD+-dependent deacetylase and/or ADP-ribosyltransferase activities. The NAD+ dependence is linking the SIRT activity to the metabolic condition of the cell, and thereby ascribed to be a pivotal metabolic sensor of mitochondrial function [65]. The seven members of the SIRT family are differentially distributed within the mammalian cells. SIRT1, SIRT2, and SIRT6 are mainly found in the nucleus, and SIRT7 in the cytosol, whereas SIRT3-5 are located in the mitochondria where they bind and deacetylate several metabolic enzymes related to energy homeostasis [66, 67].  It has been reported that SIRT3 is directly involved in regulation of ATP-production through the respiratory chain. Knockout of SIRT3 in mice resulted in decreased cellular ATP of nearly 50% in tissues that normally express high levels of ATP (e.g. liver, heart, and kidney) compared to wild-type mice. Moreover, a depletion of SIRT3 in HepG2 cells revealed a dysfunction in the ETC resulting in a dissipation of the mitochondrial membrane potential and in an increase of ROS production [68, 69]. The decrease in ATP, but also disruption of ETC function can be explained by the augmented acetylation status of complex I in SIRT3-/- mice and the involvement of SIRT3 in the deaceylation of subunits of different complexes of the respiratory chain [68]. Recent studies also showed that SOD2 activity is strongly dependent on its deacetylation status at several lysine residues. Consequently, overexpression of SIRT3 increased SOD2 activity and led to decreased cellular ROS [70, 71]. Beyond the impairment of mitochondrial energy metabolism induced by a lack of SIRT3 [72], spectrometry studies demonstrated that metabolic proteins of the TCA cycle (isocitrate dehydrogenase 2; IDH2) and β-oxidation are less deacetylated in case of metabolic stress [73, 74]. These findings are strongly underscored by the relation of SIRT3 
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deacetylation state of long-chain acyl-CoA dehydrogenase (LCAD) and diminished fatty acid oxidation (FAO) in the liver. SIRT3-/- mice depicted low FAO and thereby developed fatty liver, decreased ATP production and defective thermogenesis [75]. Besides the uncovered importance of sirtuins modulatory capabilities (see Figure 8), other involvement regarding apoptosis are currently discussed, but further studies are needed to get a comprehensive picture of sirtuins spectrum of influence. 
 
Figure 8: The SIRT3-mediated regulation in the liver illustrated by He et al. [76]. SIRT3 regulates many 
of the enzymes involved in mitochondrial metabolism. Proteins in blue, activated by SIRT3. In red, 
deactivated by SIRT3.  
2.7. Pathophysiology: Oxidative stress and mitochondrial targets of 
vulnerability The term oxidative stress describes a state where massive amounts of ROS predominate in the mitochondria. More precisely, if an initial increase of ROS is relatively low, antioxidant capacities may be sufficient enough to counteract for the increased ROS, thus cellular imbalance can be recovered to baseline conditions. However, if a certain threshold is exceeded, the antioxidant systems are no longer able to compensate excessive ROS. Oxidative stress can lead to dysfunction (DNA damage, oxidation of lipids and proteins) of the mitochondria, thereby 
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possibly initiating cellular death [78]. Oxidative stress and/or mitochondrial dysfunction can be triggered via toxins or drugs inhibiting specific functions of the mitochondria (see Figure 9).  Following paragraphs discuss most common drug off-targets, at which the mitochondria can be impaired [4, 26, 29, 39]. 
 
Figure 9: Graphic representation of various molecular off-targets that have been implicated in drug-
induced mitochondrial toxicities, adapted from Wallace et al. [39]. Abbreviations: carnitine 
palmitoyl transferase, CPT; α-ketoglutarate dehydrogenase, KDH; malate dehydrogenase, MDH; 
transporter outer membrane, TOM; transporter inner membrane, TIM. 
1. Electron transport chain & uncoupling of oxidative phosphorylation A well-defined mechanism of drug-induced mitochondrial dysfunction is the direct inhibition of the different complexes of the ETC, resulting in a diminished oxidation of substrates and oxygen consumption, finally resulting in impaired mitochondrial ATP production. In the presence of glucose, this can be compensated by glycolysis, possibly leading to lactic acidosis. Classical examples, blocking one of the five complexes of the respiratory chain include rotenone, malonate, antimycin A, cyanids, and oligomycin in the order starting from CI to CV [4]. In contrast to inhibitors of the ETC, uncouplers collaps the pH gradient and the electric potential across the IMM and thus increasing substrate 
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oxidation and oxygen consumption. The proton gradient across the IMM is dissipated as heat instead of ATP. Uncouplers are usually characterized as weak acids or bases (e.g. phenols or amids, respectively) with protonophoric activity, in order to carry protons into the mitochondrial matrix due to their permeability through the IMM (Figure 10). Laboratories performing pharmacological analysis of mitochondrial bioenergetics routinely use these known inhibitors to evaluate respiratory capacities [39].  
The impairment of the OXPHOS often results in an impairment of β-oxidation due of the lack of oxidation of NADH, which is formed during β-oxidation, but also to mtDNA damage [26].  
 
Figure 10: Mitochondrial energy production machinery and common inhibitors of the respective 
complexes of the respiratory chain adapted from Bayir and Kagan [51]. C, cytochrome c; Q, 
ubiquinone. 
 
2. Inhibition of mitochondrial substrate oxidation (FAO and Krebs’ cycle) The FAO and the Krebs’-cycle are favorite targets to be affected by many drugs that mostly mimic natural substrates. Their properties render themselves as competitive inhibitors of the respective reaction [39, 79].  As a result of the inhibition of the FAO, accumulated free fatty acids and triglycerides in the cytoplasma form small vesicles that not only influence the respiratory chain, but also inhibit the synthesis of ATP or ketone body formation, accounting for steatosis in patients. Direct inhibitors of the FAO are for example amiodarone, ibuprofen and tamoxifen. Others, such as valproic acid (VPA) or salicylic acid reach a repression via the generation of coenzyme A or L-carnitine esters leading to reduced levels of these cofactors. As opposed to direct inhibitors of the FAO, perhexiline, which is protonated in the acidic intermembrane space, 
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enters the mitochondrial matrix and thereby uncouples OXPHOS and inhibits complexes I and II of the ETC via indirect inhibition [39]. By reasons of the diversity of vulnerable target mechanisms in substrate oxidation, FAO is supposed to be one of the main causes for DILI. Therefore, several black box warnings (e.g. amiodarone, benzbromarone, tolcapone) have been raised [26]. Regarding the TCA cycle, the structural analogs fluroacetate and fluroacetamide react with oxaloacetate to form fluorocitrate, which in turn is a potent inhibitor of the aconitase enzyme in the TCA cycle. This leads then to a disturbance in the generation and delivery of reducing equivalents into the mitochondria ETC [39].  Consequently, the oxidation of incorrect substrates finally induces the same metabolic deficiency as the impairment of the ETC function through direct inhibitors. Highly metabolically active tissues or organs are therefore affected the most to misleading substrate oxidation [39] . 
3. Impairment of mitochondrial synthesis and biogenesis Several drugs have been reported to influence mtDNA and its processing such as replication and transcription [39, 43]. Most of them interact mainly with the mitochondrial polymerase γ, such as antiviral drugs (e.g. NRTIs, protease inhibitors, non NRTI) do. Some antiviral drugs can interrupt the viral life cycle by inhibiting the reverse transcription of invading viral RNA, but they may also have a high affinity to the mitochondrial polymerase 
γ. This in turn results in a reduction of mitochondrial DNA copies [41]. Topoisomerase inhibitors such as amsacrin and etopside can affect not only nuclear, but also mtDNA, possibly leading to mtDNA depletion. In addition, the antibiotic compound chloramphenicol inhibits mitochondrial protein synthesis due to high similarity of mitochondrial ribosomal RNA to eubacterial rRNA [26]. In general, mtDNA is more vulnerable to oxidative damage than nDNA due to the absence of histones and efficient repairing mechanisms in mtDNA. Additionally, the proximity of mtDNA to ROS-producing ETC renders the mitochondrial genome likely susceptible to drugs that block the respiratory chain and therefore increase mitochondrial ROS production [41].  
2.8. Mitochondria-mediated cell death: apoptosis and necrosis An impairment of mitochondrial function by oxidative stress or other factors can ultimately lead to apoptosis or necrotic cell death, as described in Figure 11. The cell can undergo cell death after the triggering of one of the two following distinct pathways, the intrinsic or extrinsic pathway, 
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both leading to a mitochondrial permeability transition (MPT). The extrinsic pathway is initiated by binding of a ligand to death receptors (e.g. TNF members) at the cell surface, whereas the intrinsic pathway originates from the mitochondria, activated mainly through oxidative stress. Excessive ROS can attack phospholipid components of the inner mitochondrial membrane thus leading to the release of cytochrome C from the mitochondria into the cytosol and thereby to an initiation of proapopotic signaling cascades [80, 81].  
 
Figure 11: Overview of the two cell-death signaling pathways apoptosis and necrosis adapted from 
Sendoel et al. [82] and Bhatia et al. [83]. Depending on variables such as ATP levels, ROS 
and/or MPT, apoptosis or necrosis can be initiated. Two distinct pathways can activate apoptosis; 
the binding of a death ligand to the death receptor initiates the extrinsic pathway resulting in an 
activation of the death-inducing signaling complex (DISC). Caspase-8 then either directly activates 
the downstream caspases or needs an amplification step via cleavage of Bid. In contrary, the 
intrinsic apoptotic signaling occurs in response to physiological signals or cellular stressors such as 
oxidative stress and DNA damage. Upon activation, the balance between antiapoptotic and 
proapoptotic Bcl-2 members on the mitochondrial membrane shifts and results in outer 
mitochondrial membrane permeabilization and cytochrome c release. Cytosolic cytochrome c binds 
to the apoptotic caspase activating factor (Apaf1) and recruits procaspase-9 to form the 
apoptosome complex. Activated caspase-9 within the apoptosome can then promote activation of 
downstream caspases.  
Background    
 23 
The MPT plays a crucial role in the activation of cell death. Factors such as oxidative stress can trigger an opening of the MPTP. The MPTP is formed by an assembly of cyclophilin D, located in the matrix, adenine nucleotide translocase (ANT) residing in the inner membrane, and porin at the outer membrane. During the opened state of this pore, molecules up to 1.5 kDa can freely pass the inner mitochondrial membrane, hence causing an excessive reentry of protons through the IMM with the result of an arrest of ATP synthesis, mitochondrial swelling and rupture of the OMM [15, 43, 84, 85].  Apoptosis occurs when cytochrome C that is located on the outer surface of the inner mitochondrial membrane, is released to the cytosol and binds to a cytoplasmic scaffold (apaf-1) and pro-caspase 9. These three proteins are forming a complex referred as apoptosome, which triggers the caspase 9 signaling downstream cascade. This involves a subsequent activation of caspase 3 and other effector caspases. Moreover activated caspase 3 binds poly (ADP-ribose) polymerase (PARP), acting as DNA repair enzyme and finally is split into small fragments. All of these down-stream effector proteins signals induce apoptotic cell death, by which resulting fragments are vanished by phagocytosis [15, 52, 86]. The control of apoptotic cascade initiation occurs via antiapoptotic proteins such as Bcl-2 that reside in the outer mitochondrial membrane and prevent cytochrome C effusion, whereas proapoptotic signals like Bax are located in the cytosol and translocate to the mitochondria in presence of death stimuli. Depending on the predominance of either Bax or Bcl, cytochrome C efflux is promoted [22]. The activation of caspases is an ATP-dependent process, where a certain functioning of the mitochondria is still required, which means that MPT has not occurred rapidly and simultaneously in all mitochondria. In contrast, the process of uncontrolled cell damage or necrosis occurs in a rapid manner simultaneously in many mitochondria, which often happens with hepatotoxins that evoke such quick cell stress. Consequently, prompt and acute depletion of mitochondrial ATP and osmotic imbalance of intra- and extracellular fluids lead to cellular swelling, a disruption of the plasma membrane, and finally to cell lysis [86].  Importantly, one has to be aware that apoptosis and necrosis are not two completely distinct processes rather than overlapping events. The extent of mitochondrial damage determines whether cell undergoes either the controlled pathway of apoptosis or necrosis, in the presence of enough ATP, apoptosis is dominant and vice versa when cellular ATP concentrations are low. Cell homeostasis can also be maintained by mitochondrial autophagy, which eliminates malfunctioning mitochondria specifically [52].  
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2.9. Mitochondrial adaptions to drugs – limiting mitochondrial injury 
and dysfunction Mitochondria have the ability to adapt to dysfunction or injury caused by toxicants or other conditions. One common mechanism to counteract oxidative stress is the enhanced expression of diverse mitochondrial antioxidant enzymes such as MnSOD and GSH peroxidase [87]. Besides that, mitochondrial biogenesis defined as the process where mitochondria are re-organized, can modulate their growth and division according to the implemented stress [88]. The proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) thereby plays a crucial role as transcriptional adaptive response to injury [31]. PGC1α is involved in the expression of antioxidant proteins but it can also bind to the peroxisome proliferator-activated receptor alpha (PPARα) and thus induces the transcriptional activation of nuclear genes encoding fatty acid metabolizing enzymes such as CPT1 or medium-chain acyl-CoA dehydrogenase (MCAD) [89]. Importantly, PGC1α is also able not only to stimulate the synthesis of nuclear encoded polypeptide of the respiratory chain during oxidative stress, but as well the transcription and replication of mitochondrial DNA [43].  The reassembly of mitochondrial morphology represents a further modulatory mechanism to mitochondrial dysfunction. As already mentioned in the section Dynamics, mitochondria constantly undergo fusion and fission in order to exchange mitochondrial content such as respiratory-chain complexes or mtDNA. In terms of injury, enhanced fusion of mitochondria may reduce oxidative stress [90, 91].  Another mechanism referred as mitochondrial hormesis has been discussed, at which constant low amounts of ROS and thus slight oxidative stress ameliorates mitochondrial biogenesis [92]. This hypothesis is supported by diverse studies revealing that caloric restriction in rodents enhanced antioxidant defense capacities [93, 94].  As a last option to counteract the mitochondrial damage to prevent cell death, impaired and affected mitochondria can be eliminated by self-digestion induced via mitochondrial autophagy (illustrated in Figure 12) [80, 95].  
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Figure 12: Various adaption mechanisms during cellular stress, adapted from Han et al. [88]. 
 
3. Current prediction methodologies for the investigation of 
mitochondrial DILI 
Predictable pharmacokinetic properties, avoidance of drug-drug interactions, and metabolic stability are possible concerns in drug development for pharmaceutical industry to keep patients safe from unexpected adverse reactions. Nevertheless, drug-induced hepatic dysfunction still accounts for many drug failures during clinical trials or the post-marketing phase, leading to drug withdrawals. Since susceptibility factors are important for idiosyncratic adverse drug reactions, this type of toxicity can usually not be detected in preclinical animal studies. Other than animal studies, mechanism-based in vitro toxicity assays have been established aiming to provide reliable models uncovering potential idiosyncratic toxicity in the preclinical phase. To date, no suitable standardized methods or biomarkers are available predicting idiosyncratic DILI. Only Hy’s law (drugs associated with clinically relevant ALT and concomitant bilirubin elevation) is commonly applied as standard procedure in clinical phases [96, 97], but this does not cover the early detection of potential drug hepatotoxicity. Therefore, it is an important need to find new approaches providing an easy-to-use and standardized method for detecting idiosyncratic DILI in preclinical drug investigation. In the following paragraph, state-of-the-art in vivo and in vitro methods and common endpoint measurements to identify mitochondrial toxicity (depicted in Figure 13) by potentially hepatotoxic drugs will be discussed.   
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Figure 13: Model of mitochondrial toxicity screening explained and illustrated by Dykens et al. [25]. 
Early identification of mitochondrial toxicity during compound series selection and lead selection 
using in vitro screens allows for structure–activity relationship (SAR) studies to circumvent it. Cell-
based screening assays are available for initial identification of general cytotoxicity. If a 
mitochondrial etiology is suspected, assessment of isolated mitochondrial function can also be 
performed in screening mode. If positive, additional in vitro mechanistic studies can examine effects 
on OXPHOS respiration, permeability transition, reactive oxygen and nitrogen centered (ROS), 
membrane potential (ΔΨ), and mitochondrial DNA (mtDNA) status, among others. Such data 
enable structure–activity relationship (SAR) studies necessary to circumvent mitochondrial toxicity. 
Mitochondrial assessment should be completed before a compound moves into further develop-
ment and is elevated to drug candidate level but should certainly also be triggered if a compound 
has a negative response in an animal model. Classical assays such as electron microscopy and 
enzyme-linked assays of the individual respiratory complexes are available for assessing 
mitochondrial status in tissues. In addition, advanced histochemical and immunohistochemical 
techniques are being developed that will help illuminate mechanism of mitochondrial impairment. 
Fostered by the organelle and cell studies, animal models are also being developed to better reveal 
mitochondrial toxicity, and hence to better predict clinical outcome.  
3.1. In vivo models Animal models are, despite the efforts to meet the 3R’s aiming to reduce, replace, and refine the use of animals in research, still essential for biomedical research as they allow controlling parameters that may be involved in the metabolism of compounds leading to adverse reaction. Above all they are favorable due to the fact that they are living organisms whereas cellular models typically lack the complex in vivo cell-cell interactions. Many attempts have been made in developing animal models for idiosyncratic DILI [98-100]. However, a lot of impediments including the lack of understanding the exact mechanisms of idiosyncratic DILI, marked inter species differences, but also the rarity of these adverse reactions led to failure in finding convincing standard approaches. Generally, normal healthy wild-type animals are used in preclinical safety studies of drug discovery but exactly these conditions do not consider the 
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inter-individual discrepancies such as genetic or environmental predispositions. Given that a toxic insult becomes pathological only if a certain critical threshold (as during oxidative stress in the mitochondria) has been reached, the chances to detect those in healthy wild-type animals equals zero. Therefore, different models have been emerged taking these factors into account by using the approach of generating transgenic animals with mitochondrial dysfunctions [101-104] or by utilizing chemicals inducing modifications of the mitochondrial function such as the mouse model with carnitine impairment. A deficiency induced by chronic exposure to the carnitine analog trimethylhydrazinium propionate results in an inhibition of fatty acid β-oxidation and hepatic steatosis [105-107].  The most promising mouse models so far specifically for idiosyncratic DILI are described as:  1) the heterozygous juvenile visceral steatosis (jvs+/-) mice exerting a carnitine deficiency generated by impaired renal reabsorption. This dysfunction led to an enhanced hepatotoxicity when mice were treated during 14 days with the antiepileptic drug valproic acid, which results in elevated levels of serum ALT, defects in the ETC, and impaired mitochondrial β-oxidation, finally leading to microvesicular steatosis. Solely (jvs+/-) mice showed this phenotype, whereas valproic acid-treated wild-type mice seemed to be unaffected [108, 109].  2) the heterozygous mitochondrial superoxide dismutase knockout mouse (SOD2+/-) with approximately 50% reduced SOD2 activity. While homozygous SOD2 mutant mice die within several days after birth due to dilated cardiomyopathy, the heterozygous strains grow normally, but showing a phenotype characteristically for mitochondrial dysfunction namely by exhibiting increased oxidative damage [101]. With this model, several drugs could be unmasked as mitochondrial toxicants such as troglitazone, nimesulide, and flutamide inducing idiosyncratic DILI [103, 110]. The observed elevation of ALT and concurrent increase in oxidative stress causing histopathological changes (hepatic necrosis) only in SOD2+/- but not in wild-type mice indicates that animals with a preexisting dysfunction of the mitochondria have a higher susceptibility to mitochondrial toxicants.  Although these two models were successful in uncovering drugs with mitochondrial idiosyncratic potency, they also bear problems such as lack of reproducibility, development of only modest liver injury, or the necessity of long-term exposure to animals. Nonetheless, the concept of generating animal models with underlying dysfunctions in order to mimic the situation in patients with predisposed diseases or dysfunction appears to be the right direction in the understanding and detection of idiosyncratic DILI.  
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3.2. In vitro models In early drug development stages, researchers are committed to detect hepatotoxicity before testing compounds in animal studies or clinical settings. Cell-based screening models reflecting human in vivo toxicity are therefore indispensable. In the following section, cellular models, which are applied currently, will be reviewed.  
Human hepatocytes Primary human hepatocytes in monolayer cultures are considered as the ‘gold standard ‘of in 
vitro toxicity testing and drug metabolism assessment due to their expression of P450 enzymes and therefore drug metabolism capacities. Nevertheless, the use of primary human hepatocytes have limitations including their instable phenotype, the large variability of hepatic function of different donors, their short viability, and their high cost and scarcity of availability [111].  
Isolated mitochondria Another approach in the evaluation of xenobiotics’ toxic mechanism is the use of isolated mitochondria (from different species). They are suitable to measure constitutional activities of oxidative phosphorylation and other mitochondrial functions based on an acute exposure to drugs [111-114]. However, one has to be cautious in interpreting results obtained from isolated mitochondria since they do not have an interaction with a physiological environment, and moreover lack the direct contact to other organelles and plasma membrane.  
Hepatoma cell lines Several hepatoma cell lines such as HepG2, HepaRG, Huh7, and Hep3b have been proposed in the study of hepatotoxicity to circumvent some disadvantages of human hepatocytes. The ease of use, the high availability, low-cost, and particularly the unlimited lifespan of immortalized cell lines render them much more favorable than using primary human hepatocytes. However, the major obstacles of these tumor-derived cell lines are on one hand the poor expression of key- metabolic enzymes making it impossible to uncover metabolizing drugs, and on the other hand the typically attribute of rapid unregulated growth of tumor cells [111, 115]. Among the human hepatoma cell lines, HepG2 cells, the most widely used and characterized system in human hepatotoxicity investigation, as well as the novel hepatoma HepaRG cells expressing subtle levels of different CYPs, are the most relevant in vitro systems in the elucidation of drug–induced mitochondrial dysfunction and toxicity (see Figure 14)[116, 117].  
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Figure 14: Light microscopy pictures of HepG2 cells (left) and differentiated HepaRG 
cells (right). HepG2 cells, usually agglomerating to small colonies, possess an 
epithelial morphology. HepaRG cells demonstrate the typical phenotype of 
clustered hepatocyte-like cells surrounded by biliary-endothelial-like cells.  
HepG2 cells  A variety of hepatotoxic compounds have been identified in HepG2 cells through mechanistic studies of determinants related to mitochondrial functions. Although HepG2 cells have similar characteristic to normal hepatocytes, the lack of relevant liver cytochrome P450 enzymes leads to misdetections or wrongly predicted cytotoxicity results [118]. Thus, a lot of effort has been made in constructing 3D systems of HepG2 cells that cover better functionalities with features including repolarization, metabolism, and transport activities that are usually lacking in classical 2D cultures [111, 115]. Since the rapid growth of the tumor-derived HepG2 cells is mostly accounted to the Crabtree effect [119], which means that they have limited mitochondrial production of ATP, which is replaced by increased glycolysis. This effect leads to a decreased vulnerability of HepG2 cells to mitochondrial toxicants. Therefore, a novel strategy has been developed to circumvent this problem. Normally, HepG2 cells are cultered in high-glucose medium (25 mM), which enables them to produce energy via glycolysis. If the culture media is replaced with galactose (10 mM), cells are forced to generate ATP mostly through OXPHOS. This makes them more susceptible to drugs with potential inhibitory effects on mitochondrial metabolism [120, 121]. For that reason, it is recommended to pay attention to the choice of culture media in order to avoid misleading results when researchers intend to screen for substances that possibly affect mitochondrial function.  
HepaRG cells Similar to HepG2 cells, HepaRG cells are also tumor-derived and therefore immortal cells. Since proliferating HepaRG cells do not exhibit any hepatic functions, they first need to be differentiated for two weeks in DMSO-containing medium so that they transform into a hepatocyte or cholangiocyte-like phenotype, which resemble closely the characteristics of 
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human hepatocytes. Unlike any other hepatoma cell line, HepaRG express 81-92% of the genes active in human hepatocytes and exert increased levels of metabolizing enzymes of phase I and II [122]. This cell line has therefore gained much attention because it allows to perform studies with drugs potentially causing toxic effects through the formation of reactive metabolites [116]. Besides these specific features, HepaRG cells can also be utilized for long-term toxicity studies due to their maintenance of metabolic function over several weeks providing important results for chronic toxicity assessment [123, 124]. Currently, HepaRG cells can be regarded as the best surrogate for primary human hepatocytes [111].  
3.3. Other approaches of hepatotoxicity testing Animal and cellular models represent the general approach to gain knowledge in drug-induced hepatotoxicity. Nevertheless, in recent years, a couple of new approaches have been developed with the aim to find relevant biomarkers or to explain mechanisms of toxic side effects [125-127]. Similar to transgenic animals, cell lines are modified via stable or transient knockdown with shRNA or siRNA, respectively [128-130], of essential genetic factors that are possibly associated with drug-induced toxicity. This technology creates conditions to comprehensively study genetic requirements in the context of drug toxicity mechanisms at which cells present deletions of genes that usually are pivotal for proper mitochondrial- or cellular functions.  The application of ‘omics’ technologies including genomics, proteomics, and metabolomics in toxicology has increased in the last few years. This field mainly describes microarray-based approaches assessing alterations in gene- or protein expression profiles induced by possible toxicants. In contrast to conventional methods, ‘omics’ provide more efficient strategies to investigate complex biological interactions and responses after exposure to toxicants [126]. Moreover they are claimed to consider strongly the interplay of genome, toxicants, and organ dysfunction, but also identify diagnostic and therapeutic fingerprints [131]. Metabolomics appears to be a promising approach to find biomarkers for hepatotoxicity due to the advantage of non-invasive sample collection and analysis [125]. Nonetheless, these technologies are still in the early stages and additional knowledge and studies are needed to judge whether these approaches will be of use as standard methods to predict toxicology in drug discovery.  
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4. Mitochondrial toxicants 
4.1. Hydroxy-cobalamin [c-lactam] (HCCL) – A vitamin B12 analog HCCL is a vitamin B12 analog that acts as a functional vitamin B12 antagonist [132]. This substance has been used to better understand morphological and functional changes occurring in the disease state of the inherited autosomal recessive disorder methylmalonic aciduria. This disease is associated with impaired activity of the enzyme methylmalonyl-Co A mutase, which may be due to mutations affecting the protein itself or due to deficient vitamin B12 transport, processing or metabolism, potentially resulting in severe metabolic-or multiorgan failure [133, 134]. It has been shown that subcutaneous administration of HCCL over several weeks in rats depicted similar pathological defects as observed in methylmalonic aciduria [135]. The competitive inhibition of hepatic L-methylmalonyl-CoA mutase leads to an impairment of propionate utilization, at which succinyl-CoA is formed and further used in the Krebs’ cycle. Propionyl-CoA and methylmalonyl-CoA are thereby increased, leading to an accumulation of toxic compounds such as urinary excreted methylmalonic acid or propionyl-derived 2-methylcitrate [132, 136]. Krahenbuhl et al. have uncovered that HCCL induces in hepatocytes of treated rats changes in mitochondrial function such as an inhibition of complexes III and IV of the mitochondrial respiratory chain. The mechanism of this inhibition is supposed to be due to defective mitochondrial RNA processing [136]. Moreover, HCCL treatment in rats has shown increased hepatic mitochondrial capacities due to mitochondrial proliferation and enlarged mitochondria [135]. HCCL appears to be an interesting compound since it chemically inhibits specific mitochondrial functions without affecting major cellular functions. HCCL may therefore represent a useful tool in establishing a cellular model or animal model with underlying mitochondrial defects to investigate mechanisms of idiosyncratic adverse drug reactions of mitochondrial toxicants.  
4.2. Azoles Azoles, a class of heterocyclic synthetic compounds, represent the most commonly used medications against fungal infections [137]. All azole derivatives, including the imidazole ketoconazole and the more recently developed triazoles such as fluconazole, posaconazole, and voriconazole share the same mechanism of action by targeting the fungal P450-dependent 
enzyme 14α-lanosterol-demethylase that is essential in the ergosterol biosynthesis of the fungal membrane [137-139]. Despite the specificity against fungal infections, adverse effects and drug-drug interaction due to high affinity to human CYPs have been implicated with azole treatment. Clinically used azoles are highly associated with the development of hepatocellular injury [9, 139, 140]. However, exact underlying mechanisms evolving the hepatotoxic etiology of azoles still 
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remain to be discovered. Some evidence about the involvement of mitochondrial toxicity leading to hepatocellular side effect is documented for ketoconazole and fluconazole [141-145]. Nevertheless, no information exists about the toxic mechanisms of the more recently released triazoles such as posaconazole and voriconazole. In the following paragraphs, the azoles used in our studies will be presented. Figure 15 depicts the chemical structures of azoles.  
 
Figure 15:  Chemical structures of the three generations of systemic azoles 
adapted from Mast et al. [146]. The numbering of some of the heteroatoms 
in posaconazole and voriconazole is also shown. 
Ketoconazole As the first antifungal agent with imidazole structure, ketoconazole was introduced to the market in the 80’s. Besides the antifungal properties, ketoconazole is a well-known inhibitor of various CYP450 isoforms [147]. Within five years after ketoconazole’s market release, increasing reports of hepatocellular adverse effects ranging from asymptomatic elevation of transaminases to fatal hepatitis became widely recognized [148, 149]. As a sanction of rising case reports of liver injury associated with ketoconazole, the FDA limited its oral use in 2013 [147].  
Fluconazole The triazole-based antifungal fluconazole was launched with an improved safety profile compared to ketoconazole. Generally, it is well tolerated and is rarely associated to hepatotoxicity [139]. Studies in rat hepatocytes have clearly shown that fluconazole’s hepatotoxic potential is only given at high concentrations, at which also impaired ETC function has been observed similar 
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to those seen with ketoconazole treatment, but with the main discrepancy that ketoconazole inhibited already at lower concentrations and with a greater extent than fluconazole [144].  
Voriconazole The second-generation triazole voriconazole has been developed with advanced properties. The low-molecular weight and water-soluble compound combines the broad spectrum of activity of itraconazole and increased bioavailability of fluconazole. Voriconazole has been recommended as the first-line therapy against invasive aspergillosis. Its indication requires caution due to significant drug-drug interactions, mainly evoked from the strong inhibitory potential against various CYPs. Therapeutic drug monitoring is necessary to control for variable plasma concentrations [140, 150].  
Posaconazole Posaconazole is the newest triazole, approved by the FDA in 2006. It shows lipophilic features and is structurally derived from itraconazole, thus revealing potent broad-spectrum activities against fungal infections. Its safety profile is similar to fluconazole and it has become an alternative to voriconazole. Nonetheless, posaconazole is implicated with hepatocellular injury [139, 151]. Since it is the most recently launched azole, little is known about the associated mechanisms of liver injury.  
4.3. Benzofuran derivatives Many reports have associated this class of drugs with hepatotoxicity. They are known to impair mitochondrial function that has been postulated as the major factor leading to severe hepatotoxicity [79].  Amiodarone, an antiarrhythmic drug was identified as potent inhibitor of mitochondrial fatty acid 
β-oxidation causing micro-and macrovesicular steatosis as well as dysfunction of the ETC and thus increased ROS production [47, 114]. These adverse properties result from amiodarone’s lipophilic characteristics, which results in accumulation in tissues such as hepatocytes. Therefore, several black box warnings from the FDA were announced [79]. Dronedarone is a follow-up compound of amiodarone, but possesses a non-iodinated benzofuran structure with additional methylsulfonamide side chain, reducing its lipophilicity [114, 152]. Despite the structural improvements dronedarone showed hepatic toxicities in the post-marketing phase with the result of a black box warning by the FDA [153]. In vivo-and in vitro studies by Felser et al. have uncovered similar mechanisms for the structural derivative of amiodarone. Impairment of 
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mitochondrial fatty acid β-oxidations is thus most likely the primary mechanism leading to the adverse effect of dronedarone [114].  Like dronedarone, benzbromarone represents a structural analog of amiodarone, but has been used as uricosuric drug. Due to reports of hepatocellular liver injury, benzbromarone was withdrawn from the market in 2003 in several countries [154]. The mechanism of its toxicity remains not fully understood. However it is also associated with mitochondrial impairment, 
including β-oxidation, activation of MPT, and mitochondrial structural changes like mitochondrial fragmentation [155].     
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Objectives 
The goal of this thesis was to contribute to an improved understanding of the molecular mechanisms of drug-induced mitochondrial dysfunction. Therefore we aimed to create models in 
vitro and in vivo with mitochondrial defects, either chemically induced or with siRNA serving as a sophisticated system to test potential hepatotoxic drugs, mimicking patients with underlying metabolic disease that are more prone to develop idiosyncratic drug-induced mitochondrial dysfunction. Another aim of the thesis was to elucidate the toxicity and associated molecular mechanisms of clinically relevant azoles that are suspected to cause idiosyncratic liver injuries as side effect.  The purpose of the first study was to establish a cellular model with subtle changes in mitochondrial function such as the respiratory chain function and to characterize beyond that the molecular mechanism of these functional impairments. We induced the dysfunction by exposing HepG2 cells to the structural vitamin B12 analog hydroxy-cobalamin [c-lactam] (HCCL) since in previous studies HCCL impaired mitochondrial bioenergetics and showed histopathological liver changes without disturbing main cellular function by competitively inhibiting major determinants of the propionate pathway. In the second study we wanted to clarify whether the changes induced by HCCL treatment previously detected in both, rat and our newly generated cell model can also be obtained in a mouse model, which would offer considerable advantages in respect of in vivo toxicological studies. If treatment with HCCL were successful and therefore confirm our hypothesis, we planned to induce specific mitochondrial dysfunction in HepG2 cells by knocking down diverse genes involved in mitochondrial energy metabolism or oxidative defense. The short report representing a pilot project hypothesized that silencing of genes, encoding for important enzymes of the mitochondria, leads to an increased liability to DILI.  The goal of the third project was to elucidate the hepatotoxicity and thereby underlying mechanisms of antifungal azole derivatives as they all feature an adverse potential of causing idiosyncratic liver injuries. In a second step, we aimed to test the hypothesis that mitochondrial toxicants are more toxic in cells with mitochondrial dysfunction (e.g. cells treated with HCCL or with knockdown of genes coding for specific mitochondrial proteins).    
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Final discussion 
Unforeseen drug-induced adverse reactions are not only one of the most feared incidences for the pharmaceutical industry but as well for health care professionals, and most importantly for patients. Such adverse reactions can lead to drug withdrawal, black box warnings and restricted use assignments [3, 11]. Although the understanding of the precise mechanisms of idiosyncratic DILI is not completely solved, research in the last few years has shown that DILI is often related with mitochondrial dysfunction [156]. Particularly preexisting or underlying mitochondrial predispositions enhance the chance of unwanted idiosyncratic toxic reactions [43]. Since no standardized guidelines exist according to which potential mitochondrial toxic drugs or new drug entities can be routinely tested, it is a need to find approaches or test systems for early discovery of idiosyncratic hepatotoxicity.   With our newly established models having subtle changes in mitochondrial function, we aimed to contribute to an increased comprehension of the complex mechanisms of mitochondrial toxicity and to the use of these models as tool of testing drugs associated with idiosyncratic mitochondrial toxicity.  
HCCL induces alterations in mitochondrial function and HepG2 cells 
treated with HCCL serve as a model for testing drugs related to 
idiosyncratic mitochondrial toxicity  The chemically modified vitamin B12 analog HCCL competitively blocks vitamin B12, which is essential for the activity of methylmalonyl-CoA mutase. MM-CoA mutase is crucial for proper catabolism of odd-chain fatty acids, and amino acids through propionate utilization [132, 135]. With HCCL, we aimed to develop a suitable cell- and mouse model with subtle mitochondrial dysfunction that can be used as a system for detecting idiosyncratic toxicity, as preexisting mitochondrial defects represent a possible risk factor that can diminish the threshold level of a mitochondrial toxicant and thus enhance the susceptibility to idiosyncratic drug reactions. Complying with our requirements for establishing a model with specific alterations in mitochondrial function, the HCCL in vitro study presented inhibition of the mitochondrial respiratory chain and other functional changes of the mitochondria without affecting main cellular homeostasis. According to the findings of Krahenbuhl et al. [136] our in vitro findings confirmed indeed a functional decrease of several complexes (CIII and CIV) of the respiratory chain, an additionally decreased mitochondrial membrane potential (ΔΨ), and a slightly 
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increased oxidative stress. Moreover, we showed that HCCL implicated structural changes such as mitochondrial swelling or alterations in mitochondrial size in vitro which comes along with our results of the in vivo study where we found increased liver weight, fat inclusions and accumulation of glycogen in the liver of mice exposed to HCCL. These observations are in agreement with the study by Krahenbuhl et al. that depicted an increased hepatic capacity of rat mitochondria after exposure to HCCL [135]. Although our mouse model did not point towards mitochondrial dysfunction observed in the in vitro study, we could show that HCCL increased MMA levels, indicating the activity of HCCL in inducing methylmalonic aciduria. Dose finding studies showed a dose-dependent elevation of MMA in blood of HCCL treated mice and functional studies after 3 weeks of daily i.p. injections of 4 mg/kg of HCCL revealed decreased activity of complex I in liver homogenate. This is different from the fndings in rats, where complex III and IV were affected [136]. This discrepancy could be explained by interspecies differences or by the possibility that HCCL continuous exposure of rats by subcutaneous mini-pumps over 6 weeks had a higher impact on mitochondrial energy function than only 3 weeks of i.p. treatment in mice. The possibility of fluctuations in HCCL plasma and tissue levels with i.p. injection could have diminished effects on mitochondrial function. However, since we found only minor changes in the liver and on mitochondrial function, and due to the lack of time, we abandoned the approach of the in vivo mouse model to test idiosyncratic toxicity and pursued the in vitro HCCL model for testing idiosyncratic toxicity. In fact, we clearly demonstrated that known mitochondrial toxicants including benzbromarone, dronedarone, and ketoconazole exert a higher toxicity in our proposed HCCL-cell model than in normal HepG2 cells, validating and emphasizing the assumption that underlying mitochondria-related diseases or dysfunctions may be important determinates in the development of idiosyncratic hepatotoxicity.  
Methodological problems and limitations We were confronted with several difficulties during the establishment of the HCCL model in HepG2 cells as for instance the choice of optimal conditions of HCCL treatment; we included different treatment conditions such as HCCL with and/or without propionate, since the used low-glucose media supplemented with amino acids may not be sufficient enough to serve as source of propionate in order to activate propionate metabolism, which is important for the effect of HCCL[157]. Interestingly, the combined treatment of HCCL and propionate was associated with increased sensitivity of HepG2 cells to mitochondrial toxicants but less mitochondrial damage as the treatment with HCCL alone. This could be explained by propionate’s toxicity itself and the augmentation of propionate and its metabolites in the conditions HCCL/propionate, which can be associated to increased hepatotoxicity [158]. 
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Moreover, it should be kept in mind that our model may be particularly useful in testing drugs where the mother substance and not a metabolite is mainly responsible for the toxicity, as HepG2 cells do not possess any adequate CYP450 activities. This difficulty can be circumvented, however, by using HepaRG cells after CYP induction with rifampicin.  Additionally, HepG2 cells maintained in glucose conditions may not be the ideal cell system to study mitochondrial defects due to their high glycolytic activities (crabtree-effect) and modified functions compared to human hepatocytes [115, 120, 121, 159], which may result in misleading results and potentially not reflecting the true effect in humans. The crabtree effect was circumvented by performing studies in the presence of galactose, which cannot be converted to glucose and favors mitochondrial ATP production.  
Knockdown of key players of mitochondrial function – suitable systems 
in detecting mitochondrial toxicants? As already mentioned, due to the paucity of models with underlying defects reflecting environmental or genetic risk factors in the development of DILI, it is a substantial necessity to create convenient models in order to understand the mechanisms of DILI and to anticipate these unwanted reactions, and above all, to early detect mitochondrial toxic agents. Although the HCCL 
in vitro model with chemically induced mitochondrial alterations appeared to be a suitable predicting model to uncover idiosyncratic toxicity, it is important to notice that there may remain the uncertainty that HCCL could implicate other unexpected cellular processes, which are not evident but still could misleadingly influence the obtained results. For this reason, we focused with the last project on the development of two cellular models with a specific knockdown of genes. The specificity of this approach should help us to understand and investigate better susceptibility factors associated with idiosyncratic toxicity. Against our hypothesis that a depletion of important enzymes of the mitochondria leads to an increased sensitivity to idiosyncratic toxicants, the results we obtained from the cytotoxicity studies neither showed an increased toxicity after treatment with different mitochondrial toxicants on cells with a siRNA-mediated knockdown of SOD2 or SIRT3 nor depicted an elevation of ROS production compared to normal HepG2 cells. Not even the additional impairment of a second mitochondrial antioxidant defense system such as the cellular GSH content could increase the susceptibility to the applied toxicants in HepG2 cells lacking SOD2. Since none of our proposed knockdown system showed any changes in the toxicity profile of mitochondrial toxicants, mitochondria may have additional compensatory mechanism that enable them to balance out the introduced defects. It appears that these systems have to be 
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reinvestigated in a more sophisticated way in order to understand better the compensatory mechanisms in cells with specific knockdown of mitochondrial enzymes or other key proteins. Furthermore, other than azole-mitochondrial toxic drugs should be tested on these models to get a larger database.  
Uncovered mitochondrial toxicity for ketoconazole and the triazole 
posaconazole – clearing up the molecular mechanisms of azole-induced 
hepatotoxicity To contribute with our knowledge about mitochondrial toxicity to clinically relevant drugs, we elucidated in the third project the problem of azole-associated hepatocellular injury. An increasing number of reports points to idiosyncratic hepatotoxicity-related side effects in many patients [9]. Mitochondrial toxicity could be a major contributor to these adverse effects. Indeed, in a few in vitro studies, mitochondrial impairment has clearly been identified as a mechanism of ketoconazole’s hepatotoxicity [9, 141, 144, 145]. We hypothesized therefore, that the current azoles in clinical use might have the same mechanism of hepatotoxicity as observed for the structurally similar imidazole ketoconazole.  We found a strong cytotoxic potential for posaconazole and, as expected, for ketoconazole; the pronounced decrease in ATP content suggested a direct involvement of mitochondrial dysfunction. Indeed, we showed damage to several mitochondrial functions in particularly an inhibition of complexes of the ETC, but as well high levels of ROS causing oxidative stress and leading to a mitochondria-induced activation of apoptosis. Moreover, additional cytotoxicity experiments in galactose-containing media to enforce ATP production via OXPHOS, revealed increased vulnerability of HepG2 cells to the exposure of ketoconazole and posaconazole, underlining the impairment of mitochondrial energy metabolism [121].  We found that fluconazole and voriconazole did not express cytotoxic effects in HepG2 cells and HepaRG cells, although many case reports evidenced hepatotoxicity with these triazoles [9]. These observations indicate that the cell systems used in our studies are not able to detect all types of hepatotoxicity. For instance, immunological liver injury cannot be detected by our systems used. The application of the mitochondrial-toxic azoles on the HCCL model in galactose-cultured HepG2 cells, which increased cytotoxicity, clearly showed that underlying defects in OXPHOS can act as susceptibility factors for mitochondrial toxicants [22]. 
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In conclusion, we have expanded the knowledge on the mechanisms of azole-induced hepatotoxicity in vitro in particular for posaconazole, since our study is the first in characterizing the molecular mechanisms of mitochondrial toxicity of posaconazole. However, further studies in human hepatocytes should be undertaken to ensure the validity of our findings. 
Promising perspectives in the early detection of DILI – future trends Taking together, our attempts to improve the knowledge of idiosyncratic mitochondrial toxicity and the establishment of suitable systems reflecting clinical manifestations of mitochondrial dysfunction as risk factor in the development of DILI were at least partially successful.  We have shown that the chemically induced modification of mitochondrial function was successful as in vitro test system for the identification of increased toxicity of mitochondrial toxicants. However, chemically induced inhibition of specific functions may alter other cellular mechanisms, which may be associated with misleading results. Therefore the approach of shutting-down specific genes and knowing their impact on a cellular level may be preferable, as they minimize the chances for affecting other metabolic processes or pathways.  Despite our knockdown models were not successful to detect idiosyncratic mitochondrial toxicity, this concept remains to be further pursued and some ideas have to be reassessed. Stable knockdown of the target genes in HepG2 cells may improve the experimental setup since the foreign DNA information is integrated in the host genome, whereas siRNA only transports the RNA to the nucleus without being integrated into the genomic information [162]. With this method chances of off-target effects such as the down regulation of multiple transcripts with sequences complementary to the siRNA seed region can be reduced [163]. In addition, cells can be kept longer in this condition, enabling them to adapt their metabolism. Moreover, the use of another cell line such as HepaRG cells that are closer to human hepatocytes could also enhance the chance of creating a suitable model for testing idiosyncratic reactions. Furthermore, search for other target genes to be silenced may also improve the concept. For example the silencing of genes that are important for proper maintenance of mitochondrial function as the transcriptional factor NF-E2-related factor 2 (Nrf2) could serve as promising model for testing mitochondrial toxicants. Our approach for the preliminary data of the siRNA model was to deplete the expression of genes that directly restore mitochondrial/cellular homeostasis. It may be of higher effectiveness to blunt Nrf2 that is a crucial nuclear factor for the activation of constitutive and inducible expression of detoxifying and antioxidant genes. Genetically modified mice that lack Nrf2 demonstrated increased susceptibility to acetaminophen-induced hepatocellular injury due to 
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reduced activation of Nrf2 –responsive genes, which are necessary for the promotion of antioxidant proteins [164]. Since the mitochondria are the major site of ROS production, silencing of Nrf2, be it in a cell assay approach or in a mouse model, could hold interesting insights in mitochondrial dysfunction and may be a useful test system in the screening of mitochondrial toxicants.  Other targets of interest could be the two key proteins mitochondrial transcription factor A (TFAM) and mitochondrial polymerase γ (POLG) implicated in the replication of mtDNA. The latter one is the only polymerase γ in the mitochondrial DNA holding a pivotal role in the replication and repair of mtDNA. It is well established that a mutation or defects of POLG lead to severe metabolic dysfunction because a depletion of mtDNA affects the synthesis of mitochondrial proteins and therefore the function of the respiratory chain [165]. TFAM belongs to the high mobility group proteins triggering mtDNA transcription in mammals that in turn lead to a generation of RNA primers necessary for the initiation of mtDNA replication [166, 167]. Knockout in mice of either TFAM or POLG showed a severe depletion of mtDNA and deficient respiratory chain function. Moreover polymorphisms in POLG have been clearly related with increased risk of mitochondrial toxicity with Nucleoside Reverse Transcriptase Inhibitor (NRTI) treatment [79]. On the basis of these findings, it would be of great value to apply those animal models or translating them into a cell model, which could serve as system with underlying mitochondrial defects. Besides the approach of gene knockdown, the development or use of sophisticated cellular 3D models with organ-like interactions are more likely to provide comprehensive results with higher value, as they reflect more physiological conditions and thereby enhance the clinical relevance of 
in vitro findings. In summary, these specified strategies could help to progress in the knowledge and development of reliable prediction methods of mitochondrial dysfunction-related DILI.  In spite of all the different aspects of generating suitable screening models, it has to be mentioned that it is most unlikely to develop one single assessment method that detects mitochondrial toxicants. Rather a combination of different approaches, as already explained in Figure 13 will enhance the predictive power to identify possible harmful drugs with high sensitivity and selectivity. To exemplify, the integrative model would subsequently incorporate data received from QSAR analysis, in vitro HTS toxicology studies and more in-depth functional assessment studies of mitochondrial dysfunction (e.g. siRNA models, isolated mitochondria) to specific animal models and toxicogenomics to determine mitochondrial toxic drugs [125]. However, this strategy will include a plethora of differently obtained data rendering it a major challenge to correctly conclude the outcomes and will not represent a fast screening method.  
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Concluding remarks Despite some impediments, with our vision of building suitable systems with which we could identify idiosyncratic mitochondrial toxicity, we have added important new insights regarding the molecular mechanisms of mitochondrial dysfunction. Our in vitro HCCL model supports the assumption that mitochondrial dysfunction reflects a crucial risk factor enhancing the adverse potential of mitochondrial toxicants. We thereby reported evidence of increased toxicity of some known mitochondrial disruptors such as benzbromarone or ketoconazole under impaired energy metabolism. Above all, our established HCCL in vitro model showed promising potential as a tool to screen for drugs that are associated with idiosyncratic adverse effects. Beyond, we have contributed new knowledge of azole-associated adverse effects by uncovering with diverse assessment methods of mitochondrial function the mechanism of ketoconazole-and posaconazole induced idiosyncratic mitochondrial toxicity in liver cells.  This thesis highlights that mitochondrial testing needs to become a fundamental tool in preclinical research, but at the same time, the choice of cell lines, culture conditions, and assessment methods always has to be well considered in order to meet the scientific questions as accurately as possible. We have learned that HepG2 cells are suitable as a preliminary tool to screen for toxicity, but they may be inappropriate for a more complex view on interacting processes, since they are tumor-derived and do not conserve main liver functions including the CYP450 enzymes.  Nevertheless it is indispensable to take notice of studies detecting mitochondrial toxicity carried out in cells that may not exactly reflect human constitution. They all contribute to an enhanced understanding of the complexity of the rare disease state of DILI. Above all, regulated guidelines systematically recording DILI associated with mitochondrial toxicity, as well as innovative testing system will be needed to improve the preclinical prediction of idiosyncratic toxicity.    
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